CAS 585543-15-3|Losmapimod

Introduction：Basic information about CAS 585543-15-3|Losmapimod, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Losmapimod BiologicalActivity
3. Chemical & Physical Properties
4. Synonyms

Common Name	Losmapimod
CAS Number	585543-15-3	Molecular Weight	383.459
Density	1.2±0.1 g/cm3	Boiling Point	529.4±50.0 °C at 760 mmHg
Molecular Formula	C₂₂H₂₆FN₃O₂	Melting Point	/
MSDS	/	Flash Point	274.0±30.1 °C

Names

Name	6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide
Synonym	More Synonyms

Losmapimod BiologicalActivity

Description	Losmapimod is a selective, potent, and orally active p38 MAPK inhibitor with pKis of 8.1 and 7.6 for p38α and p38β, respectively.
Related Catalog	Signaling Pathways >>Autophagy >>AutophagySignaling Pathways >>MAPK/ERK Pathway >>p38 MAPKResearch Areas >>Inflammation/Immunology
Target	pKi: 8.1 (p38α), 7.6 (p38β)
In Vivo	In the spontaneously hypertensive stroke-prone rat (SHR-SP), chronic treatment with GSK-AHAB significantly and dose-dependently improves survival, endothelial-dependent and -independent vascular relaxation, and indices of renal function, and it attenuates dyslipidemia, hypertension, cardiac remodeling, plasma renin activity (PRA), aldosterone, and interleukin-1β (IL-1β)[1].
Animal Admin	Male SHR-SPs (n=70) are randomly assigned according to body weight into five groups (n=14 per group): normal diet controls (ND), high salt-fat diet controls (SFD), SFD + GSK-AHAB (1.2 mg/kg/day), and SFD + GSK-AHAB (12 mg/kg/day) and SFD + rofecoxib (18 mg/kg/day). All drugs are administered in the diet by mixing with the SFD. A subgroup of animals from each group (n=6 per group) are anesthetized with isoflurane and surgically instrumented with radiotelemetry units for the conscious measurement of mean arterial blood pressure and heart rate. These animals are allowed to recover for at least 7 days before the start of the study.
References	[1]. Willette RN, et al. Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. J Pharmacol Exp Ther. 2009 Sep;330(3):964-70. [2]. Zhang XM, et al. Suppression of mitochondrial fission in experimental cerebral ischemia: The potential neuroprotective target of p38 MAPK inhibition. Neurochem Int. 2015 Nov;90:1-8.

Chemical & Physical Properties

Density	1.2±0.1 g/cm3
Boiling Point	529.4±50.0 °C at 760 mmHg
Molecular Formula	C₂₂H₂₆FN₃O₂
Molecular Weight	383.459
Flash Point	274.0±30.1 °C
Exact Mass	383.200897
PSA	78.07000
LogP	3.30
Vapour Pressure	0.0±1.4 mmHg at 25°C
Index of Refraction	1.582
InChIKey	KKYABQBFGDZVNQ-UHFFFAOYSA-N
SMILES	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1
Storage condition	-20℃

Synonyms

UNII-F2DQF16BXE

6-[5-(Cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)nicotinamide

Losmapimod

3-Pyridinecarboxamide, 6-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)-

Recommended......